Story perspectives

Breakthrough Ulcerative Colitis Drug Shows Promising Four-Year Results

10/9/2025

42 10

Summary

Story summary

Eli Lilly and Company reports mirikizumab (Omvoh) yields four-year outcomes in ulcerative colitis—the first interleukin-23 p19 (IL-23p19) biologic to provide such results.
LUCENT-3 Phase 3 results, presented at UEG Week in Berlin, show improvements.
Specifically, 78% achieved corticosteroid-free clinical remission and 93% reported reduced bowel urgency.
Safety remained consistent: 12% had serious adverse events; 7% discontinued due to adverse events.

1 of 1

Story summary

Eli Lilly and Company reports mirikizumab (Omvoh) yields four-year outcomes in ulcerative colitis—the first interleukin-23 p19 (IL-23p19) biologic to provide such results.
LUCENT-3 Phase 3 results, presented at UEG Week in Berlin, show improvements.
Specifically, 78% achieved corticosteroid-free clinical remission and 93% reported reduced bowel urgency.
Safety remained consistent: 12% had serious adverse events; 7% discontinued due to adverse events.